Capricor Therapeutics (NASDAQ:CAPR) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPRFree Report) in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a buy rating in a report on Wednesday, September 25th. Oppenheimer reissued an outperform rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Finally, Cantor Fitzgerald reaffirmed an overweight rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $22.60.

Get Our Latest Analysis on Capricor Therapeutics

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $17.77 on Wednesday. The company has a market capitalization of $568.27 million, a P/E ratio of -20.43 and a beta of 4.01. The business has a 50-day moving average of $7.44 and a two-hundred day moving average of $6.07. Capricor Therapeutics has a 1 year low of $2.68 and a 1 year high of $21.98.

Capricor Therapeutics (NASDAQ:CAPRGet Free Report) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, equities analysts anticipate that Capricor Therapeutics will post -1.13 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, with a total value of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at $38,004,281.36. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in shares of Capricor Therapeutics during the 1st quarter worth about $40,000. SG Americas Securities LLC bought a new position in Capricor Therapeutics during the third quarter worth about $133,000. Main Street Financial Solutions LLC grew its holdings in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the second quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

(Get Free Report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Stories

Analyst Recommendations for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.